ExposeIQ expands JuryFit for pharmaceutical litigation jury selection

ExposeIQ said its JuryFit platform now gives pharmaceutical litigation teams human-verified juror analysis and trial simulation tools aimed at improving jury selection in complex product liability cases. The update targets cases shaped by scientific evidence, regulatory issues and strong juror attitudes about medicine and corporate accountability.

Why it matters: - Pharmaceutical trials often turn on how jurors react to science, risk, corporate conduct and patient safety. - ExposeIQ says JuryFit is meant to help trial teams identify jurors who may be more or less receptive to a case theory before a panel is seated. - The platform is positioned to support more consistent jury selection in high-stakes product liability matters.

What happened: - ExposeIQ announced expanded capabilities in its JuryFit platform on July 8, 2026. - The update is aimed at pharmaceutical litigation teams handling complex product liability cases. - JuryFit evaluates case theories against multiple juror dimensions, including demographics, life experiences, attitudes and beliefs, political and social values, personality and cognitive traits, and implicit and explicit biases. - The platform uses a human verification process with licensed professionals to review assessments before they are used.

The details: - JuryFit identifies combinations of juror factors that may affect whether a juror is predisposed to accept a theory of the case. - The platform generates targeted Voir Dire questions from that analysis. - Those questions also go through human verification before they are added to the jury selection strategy. - After a jury is empaneled, attorneys can test arguments, scientific explanations and damages themes against a Virtual Mirror Jury™. - The Virtual Mirror Jury™ is built to reflect the personality profiles and group dynamics of the seated jurors. - ExposeIQ said all outputs from the Virtual Mirror Jury process are subject to human verification.

Between the lines: - The launch reflects a broader push to blend litigation analytics with human review in an area where fully automated jury scoring would be hard to trust. - ExposeIQ is pitching professional oversight as a safeguard against overreliance on predictive tools in emotionally charged trials. - Joseph Terp, ExposeIQ co-founder and CEO, said pharmaceutical cases require jurors to weigh complex evidence while navigating personal beliefs about corporate conduct and patient safety.

What's next: - Trial teams using JuryFit can apply the platform during voir dire and after a jury is seated. - ExposeIQ says the system is intended to help attorneys make more informed strategic decisions throughout the litigation process. - The company will likely continue positioning JuryFit around complex litigation where juror bias and scientific complexity are central issues.

The bottom line: - ExposeIQ is adding human-verified juror analysis and simulation tools to help pharmaceutical defense teams sharpen jury selection strategy without surrendering final judgment to software.